Amniotics

Rwanda
Byumba, Northern Province, Rwanda, 223 63

Company profile

Amniotics company profile

Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the University Hospital of Lund, the company is pioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC). These stem cells have unique properties for applications in regenerative medicine. Amniotics has also an, by Läkemedelsverket (MPA in Sweden), approved GMP (Good Manufacturing Practice) manufacturing facility to produce Advanced therapy medicinal products (ATMPs). With the GMP facilities operational since 2020, Amniotics is now moving into clinical trials with the leading drug candidate, PulmoStem™ and is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0-$1M
Founded
2015-01-01, Year

Headquarters

Postal code
223 63
Country code
RW
Continent
Africa

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
2
Total equity funding
$2.1M
Last funding
Series Unknown / 2021-01-12
Last equity funding
Series Unknown
Investors
2
Founders
1
Articles
20
Exited on
2021-07-06

Founders and investors

Founders

Marcus Larsson

Investors

Almi InvestLU Innovation